Merck (MRK) Updates on KEYTRUDA Phase 1b KEYNOTE-028 Study; Clinical Activity, Durable Responses Observed
Tweet Send to a Friend
Merck (NYSE: MRK) announced that updated findings from the phase 1b KEYNOTE-028 study investigating the use of KEYTRUDA (pembrolizumab), the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
